Antagonism of VEGF-A-induced increase in vascular permeability by an integrin alpha 3 beta 1-Shp-1-cAMP/PKA pathway

作者：Kim Soo Hyeon; Cho Young Rak; Kim Hyeon Ju; Oh Joa Sub; Ahn Eun Kyung; Ko Hye Jin; Hwang Byung Joon; Lee Seo Jin; Cho Yongwan; Kim Yong Kee; Stetler Stevenson William G^*; Seo Dong Wan

来源：Blood, 2012, 120(24): 4892-4902.

DOI：10.1182/blood-2012-05-428243

In cancer, VEGF-induced increase in vascular permeability results in increased interstitial pressure, reducing perfusion and increasing hypoxia, which reduce delivery of chemotherapeutic agents and increase resistance to ionizing radiation. Here, we show that both TIMP-2 and Ala + TIMP-2, a TIMP-2 mutant without matrix metalloproteinase inhibitory activity, antagonize the VEGF-A-induced increase in vascular permeability, both in vitro and in vivo. Like other agents known to preserve endothelial barrier function, TIMP-2 elevates cytosolic levels of cAMP and increases cytoskeletal-associated vascular endothelial cadherin in human microvascular endothelial cells. All of these effects are completely ablated by selective knockdown of integrin alpha 3 beta 1 expression, expression of a dominant negative protein tyrosine phosphatase Shp-1 mutant, administration of the protein tyrosine phosphatase inhibitor orthovanadate, or the adenylate cyclase inhibitor SQ22536. This TIMP-2-mediated inhibition of vascular permeability involves an integrin alpha 3 beta 1-Shp-1-cAMP/protein kinase A-dependent vascular endothelial cadherin cytoskeletal association, as evidenced by using siRNAs to integrin alpha 3 beta 1 and Shp-1, or treatment with Shp-1 inhibitor NSC87877 and protein kinase A inhibitor H89. Our results demonstrate the potential utility for TIMP-2 in cancer therapy through %26quot;normalization%26quot; of vascular permeability in addition to previously described antiangiogenic effects. (Blood. 2012;120(24):4892-4902)

• 出版日期2012-12-6